A screen to identify drug resistant variants to target-directed anti-cancer agents

Biological Procedures Online

Volumn 5, Issue 1, 2003, Pages 204-210

  Azam, Mohammad ^a   Raz, Tal ^a   Nardi, Valentina ^a   Opitz, Sarah L ^a   Daley, George Q ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Chronic myeloid leukemia; Drug resistance; Genes, ABL

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PROTEIN KINASE; RETROVIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; MITOGENESIS; NONHUMAN; ONCOGENE; PATIENT MONITORING; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0346670259     PISSN: 14809222     EISSN: None     Source Type: Journal    
DOI: 10.1251/bpo63     Document Type: Article

References (10)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5):561-566.
2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
3. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2:296-313.
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
7. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99(9):3472-3475.
8. Azam M, Latek LR, Daley GQ. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell 2003; 112:831-843.
9. Koh EY, Chen T, Daley GQ. Enhanced cDNA Rescue Strategies to Facilitate Functional Genomic/Phenotypic Screens in Mammalian Cells. Nucleic Acids Res 2002; 30:E142-2.
10. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988; 85:9312-9316.